Table 1.

HAVEN 1 annualized bleeding rates.

	Group A: emicizumab prophylaxis (n = 35)	Group B: no prophylaxis (n = 18)	Group C: emicizumab prophylaxis (n = 49)
All bleeding events: annualized bleeding rate (95% CI); % reduction	5.5 (3.58–8.60)	28.3 (16.79–47.76)	6.5 (3.43–12.43)
	80% (0.20), p < 0.0001
Treated bleeding events: annualized bleeding rate (95% CI); % reduction	2.9 (1.69–5.02)	23.3 (12.33–43.89)	5.1 (2.28–11.22)
	87% (0.13), p < 0.0001
% participants with zero bleeds (95% CI)	62.9 (44.9–78.5)	5.6 (0.1–27.3)	69.4 (54.6–81.7)

HAVEN 1: prophylactic emicizumab versus no prophylaxis in hemophilia A patients with inhibitors.⁵²

CI, confidence interval.